Sector Expert: Joseph Pantginis

ROTH Capital Partners

Image: Joseph Pantginis

Joseph Pantginis, Ph.D., joined ROTH Capital Partners in 2009. Prior to joining ROTH, Pantginis was a senior biotech analyst at Merriman Curhan Ford (now Merriman Holdings Inc.). Pantginis was also a senior biotechnology analyst at Canaccord Adams, focusing on the oncology, inflammation and infectious disease spaces. Prior to Canaccord Adams he was a biotech analyst at several firms, including JBHanauer & Co., First Albany Corp., Commerce Capital Markets Inc. and Ladenburg Thalmann & Co. Inc. Prior to his tenure on Wall Street, Pantginis served as an associate manager/scientist of Regeneron Pharmaceuticals' Retrovirus Core Facility. Pantginis received a master's degree in business administration (finance) from Pace University; a doctorate in molecular genetics and a master's degree from Albert Einstein College of Medicine; and a bachelor's degree from Fordham University.

Subscribe to
Streetwise Reports
Ask this Expert

Companies Commented On

  • AmpliPhi Biosciences
  • Applied Genetic Technologies Corp.
  • Argos Therapeutics Inc.
  • BioBlast Pharma
  • BioLineRx Ltd.
  • Can-Fite BioPharma Ltd.
  • Celator Pharmaceuticals Inc.
  • Concert Pharmaceuticals
  • ContraFect Corp.
  • CTI BioPharma
  • Cytokinetics Inc.
  • DelMar Pharmaceuticals Inc.
  • Immune Pharmaceuticals Inc.
  • ImmunoCellular Therapeutics Ltd.
  • Lion Biotechnologies
  • MEI Pharma Inc.
  • OncoSec Medical Inc.
  • Oncothyreon Inc.
  • Palatin Technologies Inc.
  • Paratek Pharmaceuticals Inc.
  • Peregrine Pharmaceuticals Inc.
  • Prima BioMed Ltd.
  • Rexahn Pharmaceuticals Inc.
  • ROTH Capital Partners
  • Spectrum Pharmaceuticals Inc.
  • Stemline Therapeutics Inc.
  • Sunesis Pharmaceuticals Inc.
  • Synta Pharmaceuticals Corp.
  • Telesta Therapeutics Inc.
  • TG Therapeutics Inc.
  • Threshold Pharmaceuticals Inc.
  • VBL Therapeutics
  • Verastem Inc.
  • Viralytics Ltd.


Recent Interviews

Capitalize on Comeback Stories in Micro-Cap Biotech: Joe Pantginis of ROTH Capital Partners (6/17/15)
redpetridish580

The list of problems with investing in micro-cap biotech stocks begins with extreme volatility and lack of liquidity and ends with the inability to get validation from sophisticated investors who are unable to own such small companies. Nevertheless, sift through the pile and investors can find gems. Joseph Pantginis of ROTH Capital Partners recognizes the characteristics that make some of these tiny companies move up the ladder in market valuation. In this interview with The Life Sciences Report, Pantginis discusses five names with development programs capable of generating dramatic growth.

A Bull Run Hiccup: 2015 Small-Cap Biotech Watchlist Update (5/13/15)

It's been four months since The Life Sciences Report's 2015 Small-Cap Biotech Watchlist was announced at the Biotech Showcase in San Francisco. The year is off to a bumpy start, though the rough ride is not predicated, necessarily, on individual company performance. Read on for highlights of the Watchlist's Q1/15 performance.

Watchlist Analysts Forecast Continued Blue Sky for Biotech Industry (1/29/15)
2015watchlist580

For the last two years the biotech sector has experienced market-beating gains, even taking into account the industry-wide hiccup in early 2014. Can this trend continue? The five analysts who selected names for The Life Sciences Report's 2015 Small-Cap Biotech Watchlist spend their days considering this question; it comes into play with every recommendation they make. The topic came up in various contexts during the Watchlist panel at the 2015 Biotech Showcase: Here are four factors investors should consider as they move into 2015.

Recent Quotes

"CPXX's Vyxeos represents the first potential meaningful improvement to treating AML in decades."

— Joseph Pantginis, ROTH Capital Partners (12/8/15)
more >

"CPXX's Vyxeos (CPX-351) continues to show improved safety."

— Joseph Pantginis, ROTH Capital Partners (12/6/15)
more >

"We believe IMUC's Phase 3 trial of ICT-107 should show a survival benefit."

— Joseph Pantginis, ROTH Capital Partners (11/25/15)
more >

"IMUC showed a survival benefit for ICT-107 in defined subgroups."

— Joseph Pantginis, ROTH Capital Partners (11/22/15)
more >

"IMUC's ICT-107 Phase 3 study is now screening patients."

— Joseph Pantginis, ROTH Capital Partners (11/11/15)
more >

"Early data flow from RNN's three drugs is now in full swing."

— Joseph Pantginis, ROTH Capital Partners (11/6/15)
more >

"With a sole focus on oncology, RNN is prepped for success."

— Joseph Pantginis, ROTH Capital Partners (11/3/15)
more >

"CPXX is approaching a major binary catalyst, survival data, in Q1/16."

— Joseph Pantginis, ROTH Capital Partners (10/26/15)
more >

more comments

"CPXX has concluded its required Phase 2 study of Vyxeos."

— Joseph Pantginis, ROTH Capital Partners (10/21/15)
more >

"RNN has started the data flow, and we look forward to the start of its broad Phase 2 program."

— Joseph Pantginis, ROTH Capital Partners (9/28/15)
more >

"IMUC received an SPA for start of the ICT-107 study in glioblastoma."

— Joseph Pantginis, ROTH Capital Partners (8/13/15)
more >

"CPXX's Vyxeos could be a meaningful improvement to treating AML."

— Joseph Pantginis, ROTH Capital Partners (8/11/15)
more >

"RNN posted a Q2/15 EPS of ($0.02) and $26M in cash."

— Joseph Pantginis, ROTH Capital Partners (8/10/15)
more >

"We reiterate our Buy rating for CPXX and are raising our target price."

— Joseph Pantginis, ROTH Capital Partners (7/26/15)
more >

"KOLs have enthusiasm and belief in CPXX's Vyxeos following the response rates observed in the Phase 2."

— Joseph Pantginis, ROTH Capital Partners (7/17/15)
more >

"We continue to be impressed by the physician commentary surrounding CPXX's CPX-351 data."

— Joseph Pantginis, ROTH Capital Partners (7/14/15)
more >

"We believe that CPXX's CPX-351 has significantly more room to grow."

— Joseph Pantginis, ROTH Capital Partners (6/24/15)
more >

"The intriguing component of SNSS' VALOR study is a nice survival benefit seen in patients 60 years and older."

The Life Sciences Report Interview with Joe Pantginis (6/17/15)
more >

"RNN is playing in the right space of targeted therapies."

The Life Sciences Report Interview with Joe Pantginis (6/17/15)
more >

"IMUC is a very intriguing name."

The Life Sciences Report Interview with Joe Pantginis (6/17/15)
more >

"CPXX is improving the current standard of care in acute myeloid leukemia."

The Life Sciences Report Interview with Joe Pantginis (6/17/15)
more >

"Following the 12-week endpoint, CANF's CF101 continued accumulation and the responses have become much better."

The Life Sciences Report Interview with Joe Pantginis (6/17/15)
more >

"We believe SNSS' subgroup analyses could be meaningful to regulators."

— Joseph Pantginis, ROTH Capital Partners (6/15/15)
more >

"CPXX announced expansion of one cohort in the MDS/AML CPX-351 study."

— Joseph Pantginis, ROTH Capital Partners (6/8/15)
more >

"CPXX's Phase 3 data release this month represents a major catalyst."

— Joseph Pantginis, ROTH Capital Partners (6/3/15)
more >

"The recent resurgence of CANF's psoriasis program is encouraging."

— Joseph Pantginis, ROTH Capital Partners (5/31/15)
more >

"In SNSS' VALOR study, subgroups showed improved overall survival."

— Joseph Pantginis, ROTH Capital Partners (5/21/15)
more >

"SNSS is targeting its formal meeting with the FDA in mid-2015 and, if successful, a rolling NDA submission in H2/15."

The Life Sciences Report 2015 Small-Cap Biotech Watchlist Update with Joe Pantginis (5/13/15)
more >

"We believe the RNN story is prepped for success."

— Joseph Pantginis, ROTH Capital Partners (5/11/15)
more >

"The induction CR/CRi rate later in Q2/15 is a major catalyst for CPXX."

— Joseph Pantginis, ROTH Capital Partners (5/7/15)
more >

"SNSS targets meeting with the FDA and the EMA in mid-2015."

— Joseph Pantginis, ROTH Capital Partners (5/5/15)
more >

"Important background activities continue at SNSS."

— Joseph Pantginis, ROTH Capital Partners (4/27/15)
more >

"CANF announced it will resume its psoriasis program for CF101."

— Joseph Pantginis, ROTH Capital Partners (4/27/15)
more >

"CANF's agreement with Cipher validates the commitment to CF101."

— Joseph Pantginis, ROTH Capital Partners (3/23/15)
more >

"CANF completed development of the commercial biomarker test for A3AR."

— Joseph Pantginis, ROTH Capital Partners (3/18/15)
more >

"RNN's Phase 1 Supinoxin and RX-3117 studies wrap up around mid-2015."

— Joseph Pantginis, ROTH Capital Partners (3/17/15)
more >

"This year should be a turning point for IMUC, so we reiterate our Buy rating."

— Joseph Pantginis, ROTH Capital Partners (3/13/15)
more >

"We see upside for SNSS shares in 2015."

— Joseph Pantginis, ROTH Capital Partners (3/13/15)
more >

"We believe 2015 will see a flurry of activity out of DMPI."

— Joseph Pantginis, ROTH Capital Partners (2/18/15)
more >

"CANF's Phase 2/3 study of CF101 in plaque psoriasis patients is complete; we believe now is a good time to buy."

— Joseph Pantginis, ROTH Capital Partners (2/4/15)
more >

"We have high confidence in CPXX's CPX-351, which meets a continuing unmet medical need."

— Joseph Pantginis, ROTH Capital Partners (1/20/15)
more >

"SNSS shares should perform well in 2015."

— Joseph Pantginis, ROTH Capital Partners (12/15/14)
more >

"We reiterate our Buy rating for CPXX."

— Joseph Pantginis, ROTH Capital Partners (12/8/14)
more >

"DMPI has a valuable, novel asset with distinguishing attributes."

— Joseph Pantginis, ROTH Capital Partners (11/17/14)
more >

"65% of the target group for IMUC's ICT-107 Phase 2 trial are alive compared to 50% in the control group."

— Joseph Pantginis, ROTH Capital Partners (11/14/14)
more >

"In Q3/14, SNSS reported EPS of $0.25, beating our estimate and the consensus."

— Joseph Pantginis, ROTH Capital Partners (11/11/14)
more >

"The FDA gave orphan status to RNN's RX-3117 for pancreatic cancer."

— Joseph Pantginis, ROTH Capital Partners (9/24/14)
more >

"We see significant partnering potential for CANF's rheumatoid arthritis drug."

— Joseph Pantginis, ROTH Capital Partners (9/2/14)
more >

"The RNN story can now be viewed as a ground floor opportunity."

— Joseph Pantginis, ROTH Capital Partners (8/14/14)
more >

"The RNN story can now be viewed as an emerging opportunity."

— Joseph Pantginis, ROTH Capital Partners (7/18/14)
more >

"RNN's RX-3117 has potential to be a sleeper product candidate."

The Life Sciences Report Interview with Joseph Pantginis (6/5/14)
more >

"CYTX believes it has hit the points on the checklist to move to the next option of the Celution BARDA study, which could be worth up to $35M."

The Life Sciences Report Interview with Joseph Pantginis (6/5/14)
more >

fewer comments


Due to permission requirements, not all quotes are shown.